Profil Kasus Tuberkulosis Resisten Obat di RSUP Dr. Soeradji Tirtonegoro Klaten Periode Tahun 2012-2017

Authors

  • Alifia Rimadhani Yuwono Program Studi Farmasi, Fakultas Ilmu Kesehatan, Universitas Darussalam Gontor
  • Surya Amal Program Studi Farmasi, Fakultas Ilmu Kesehatan, Universitas Darussalam Gontor
  • Lija Oktya Artanti Program Studi Farmasi, Fakultas Ilmu Kesehatan, Universitas Darussalam Gontor

DOI:

https://doi.org/10.21111/pharmasipha.v2i2.3039

Keywords:

tuberculosis, drug resistance, RSUP Dr.Soeradji Tirtonegoro hospital, 2012-2017

Abstract

DR TB (Drug Resistance Tuberculosis) is the resistance of Micobacterium tuberculosis to anti-tuberculosis drugs. These study aims are to observe and identify the case profile of drug-resistant tuberculosis, which includes patient characteristics and resistance patterns of Micobacterium tuberculosis against ATD at dr. Soeradji Tirtonegoro Klaten. The type of research is descriptive-retrospective based on secondary data from laboratory data and medical records in the period 2012-2017. Sampling was done by total sampling technique. Obtained a total population of TB patients resistant was 15 patients with 10 patients who met the inclusion criteria expressed in the study sample. Characteristics of patients with drug-resistant tuberculosis, mostly found were female (60%) with an age range of 60-70 years (40%). Mostly origins of Klaten (central region) (90%). The educational status was high school graduated (50%), not working (60%), comorbidities were bronchiectasis (15.4%), the nutritional status was underweight (60%), and suffering the pulmonary TB (70%). The result of this study showed the resistance patterns were primary resistance (50%) and secondary resistance (50%). Resistant to 1 ATD (60%), 2 ATD (30%), 3 ATD (10%). The highest resistance was monoresistant streptomycin (20%), ethambutol (20%), rifampicin (10%), Isoniazid(10%). Polyresistant found was the combination of ethambutol and streptomycin (30%). MDR TB incidence (10%) was the combination of rifampicin + ethambutol + streptomycin. The highest sensitivity

Downloads

Published

2018-09-15

Issue

Vol. 2 No. 2 (2018): September

Section

Articles

License

Authors who publish with this Journal agree to the following terms:

  1. Author retain copyright and grant the journal right of first publication with the work simultaneously licensed under a creative commons attribution license that allow others to share the work within an acknowledgement of the work’s authorship and initial publication of this journal.
  2. Authors are able to enter into separate, additional contractual arrangement for the non-exclusive distribution of the journal’s published version of the work (e.g. acknowledgement of its initial publication in this journal).
  3. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on their websites) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published works.